Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KRRO with free AI briefings, catalyst countdowns, and dilution alerts.

KRRO · Korro Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$124.8M Cash on Hand
25mo Cash Runway
Follow KRRO by email Get an email when KRRO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KRRO, unsubscribe in one click. Privacy

📣 What KRRO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
KRRO-110 Alpha-1 Anti-trypsin Deficiency Phase 1/2 · NCT06677307 Terminated
KRRO-121 Urea Cycle Disorders, Inborn Phase 1/2 · NCT07773246 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KRRO holds $124.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $15M/quarter from operations, an estimated runway of 25 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KRRO files for a raise →

👥 Who Owns KRRO

Insiders 23.5% Other 5%+ holders 16.7% Institutions (156 holders) 59.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Lynx1 Capital Management LP
10% owner
Insider 1,624,789 11.84% 2026-10-22
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 1,474,162 10.74% 2026-09-30
Mohamad Makhzoumi
10% owner · +242,945 options
Insider 1,297,893 9.46% 2026-03-10
Carmen Chang
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Scott D Sandell
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Forest Baskett
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
New Enterprise Associates 17, L.P.
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Edward T Mathers
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Rick Yang
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Anthony A. Jr. Florence
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Paul Edward Walker
10% owner · +242,945 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10
Ali Behbahani
Director · +257,622 options
Includes shares also reported by Mohamad Makhzoumi, counted once
Insider 1,297,893 9.46% 2026-03-10

Share count 13,725,646 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KRRO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRRO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.